Interventional firm Thoratec of Pleasanton, CA, has signed a new agreement with C.R. Bard subsidiary Impra, which will gain additional distribution rights to Thoratec’s Vectra vascular access graft (VAG). Impra also receives exclusive marketing and distribution rights in Europe and selected countries in Scandinavia, the Middle East, and northern Africa.
Impra has been distributing Vectra VAG in the U.S. since mid-2001. The new deal runs through 2006, and can be extended, according to Thoratec.
By AuntMinnie.com staff writersJanuary 25, 2002
Related Reading
Mallinckrodt owner Tyco to split into four companies, January 23, 2002
Bard shareholders approve Tyco deal, August 8, 2001
Tyco to acquire C.R. Bard, May 30, 2001
Bard gets clearance for biliary stent, April 17, 2001
Bard to test ePTFE-covered stent, March 8, 2001
Copyright © 2002 AuntMinnie.com
